Open-label Multicenter, Phase I/II Study Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal Neovascularisation (CNV) Secondary to Age-related Macular Degeneration (AMD)

Trial Profile

Open-label Multicenter, Phase I/II Study Assessing the Safety and Efficacy of Ranibizumab (RFB002) in Japanese Patients With Subfoveal Choroidal Neovascularisation (CNV) Secondary to Age-related Macular Degeneration (AMD)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Age-related macular degeneration; Choroidal neovascularisation
  • Focus Therapeutic Use
  • Acronyms EXTEND-I
  • Sponsors Novartis
  • Most Recent Events

    • 15 Aug 2014 New trial record
    • 17 Nov 2006
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top